329909-29-7 Usage
General Description
3-Fluoro-4-methylbenzenesulfonamid, also known as 3-fluoro-4-methylbenzenesulfonamide, is a chemical compound with the molecular formula C7H8FNO2S. It is a sulfonamide derivative that contains a fluorine atom and a methyl group attached to a benzene ring. 3-FLUORO-4-METHYLBENZENESULFONAMID& is commonly used in the pharmaceutical and agrochemical industries as a building block for the synthesis of various biologically active compounds. It is also used as a reagent in organic synthesis and as an intermediate in the production of fine chemicals. 3-Fluoro-4-methylbenzenesulfonamid is a white solid with a high melting point and is typically stored and handled under strict laboratory conditions due to its potential health hazards and reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 329909-29-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,9,9,0 and 9 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 329909-29:
(8*3)+(7*2)+(6*9)+(5*9)+(4*0)+(3*9)+(2*2)+(1*9)=177
177 % 10 = 7
So 329909-29-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H8FNO2S/c1-5-2-3-6(4-7(5)8)12(9,10)11/h2-4H,1H3,(H2,9,10,11)
329909-29-7Relevant articles and documents
FLUORO-CONTAINING COMPOUNDS, USE AND PREPARATION THEREOF
-
Paragraph 0176; 0177, (2019/02/02)
The present teachings relate to a fluoro-containing compound, a composition thereof, a method of using the compound or the composition in treating a disease, and a method of preparing the compound. In a particular example, the compound is chosen from Form
PROCESS FOR MAKING N-SULFONATED-AMINO ACID DERIVATIVES
-
Page/Page column 11; 13-15; 40-41, (2008/06/13)
This invention relates to a process for preparing optically active α -amino acid substrates which are used to make potent lethal factor (LF) inhibitors for the treatment of anthrax. This invention further relates to a process for synthesis of potent LF-inhibitors for the treatment of anthrax. Specifically, the invention concerns a novel, high-yielding and highly enantioselective asymmetric hydrogenation reaction of a tetrasubstituted ene-sulfonamide acid or ester.
